vs
ICU MEDICAL INC（ICUI）与医疗房产信托（SVC）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是医疗房产信托的1.8倍（$540.7M vs $296.5M），医疗房产信托净利率更高（-0.3% vs -2.9%，领先2.6%），ICU MEDICAL INC同比增速更快（-14.1% vs -17.0%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-95.2M），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -6.1%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
医疗房产信托（MPT）是总部位于阿拉巴马州伯明翰的国际房地产投资信托（REIT），主要在美国和欧洲地区收购投资医疗设施与营利性医疗控股公司。该公司的房产收购多采用售后回租模式，原产权方出售房产给MPT后成为承租租户，其租户普遍签订长期三净租约。
ICUI vs SVC — 直观对比
营收规模更大
ICUI
是对方的1.8倍
$296.5M
营收增速更快
ICUI
高出2.8%
-17.0%
净利率更高
SVC
高出2.6%
-2.9%
自由现金流更多
ICUI
多$131.1M
$-95.2M
两年增速更快
ICUI
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $296.5M |
| 净利润 | $-15.7M | $-782.0K |
| 毛利率 | 37.5% | — |
| 营业利润率 | 1.0% | -3.9% |
| 净利率 | -2.9% | -0.3% |
| 营收同比 | -14.1% | -17.0% |
| 净利润同比 | 34.0% | 99.0% |
| 每股收益（稀释后） | $-0.63 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUISVC
| Q4 25 | $540.7M | $296.5M | ||
| Q3 25 | $537.0M | $377.6M | ||
| Q2 25 | $548.9M | $404.4M | ||
| Q1 25 | $604.7M | $335.0M | ||
| Q4 24 | $629.8M | $357.0M | ||
| Q3 24 | $589.1M | $390.9M | ||
| Q2 24 | $596.5M | $412.5M | ||
| Q1 24 | $566.7M | $336.2M |
净利润ICUISVC
| Q4 25 | $-15.7M | $-782.0K | ||
| Q3 25 | $-3.4M | $-46.9M | ||
| Q2 25 | $35.3M | $-38.2M | ||
| Q1 25 | $-15.5M | $-116.4M | ||
| Q4 24 | $-23.8M | $-76.4M | ||
| Q3 24 | $-33.0M | $-46.9M | ||
| Q2 24 | $-21.4M | $-73.8M | ||
| Q1 24 | $-39.5M | $-78.4M |
毛利率ICUISVC
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 32.7% | — |
营业利润率ICUISVC
| Q4 25 | 1.0% | -3.9% | ||
| Q3 25 | 2.6% | -12.8% | ||
| Q2 25 | 1.9% | -9.2% | ||
| Q1 25 | 2.1% | -33.3% | ||
| Q4 24 | 6.0% | -19.4% | ||
| Q3 24 | 1.4% | -12.8% | ||
| Q2 24 | 1.3% | -17.1% | ||
| Q1 24 | -1.9% | -21.4% |
净利率ICUISVC
| Q4 25 | -2.9% | -0.3% | ||
| Q3 25 | -0.6% | -12.4% | ||
| Q2 25 | 6.4% | -9.4% | ||
| Q1 25 | -2.6% | -34.8% | ||
| Q4 24 | -3.8% | -21.4% | ||
| Q3 24 | -5.6% | -12.0% | ||
| Q2 24 | -3.6% | -17.9% | ||
| Q1 24 | -7.0% | -23.3% |
每股收益（稀释后）ICUISVC
| Q4 25 | $-0.63 | $-0.01 | ||
| Q3 25 | $-0.14 | $-0.28 | ||
| Q2 25 | $1.43 | $-0.23 | ||
| Q1 25 | $-0.63 | $-0.70 | ||
| Q4 24 | $-0.97 | $-0.46 | ||
| Q3 24 | $-1.35 | $-0.28 | ||
| Q2 24 | $-0.88 | $-0.45 | ||
| Q1 24 | $-1.63 | $-0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $346.8M |
| 总债务越低越好 | — | $5.5B |
| 股东权益账面价值 | $2.1B | $646.1M |
| 总资产 | $4.1B | $6.5B |
| 负债/权益比越低杠杆越低 | — | 8.52× |
8季度趋势，按日历期对齐
现金及短期投资ICUISVC
| Q4 25 | — | $346.8M | ||
| Q3 25 | — | $417.4M | ||
| Q2 25 | — | $63.2M | ||
| Q1 25 | — | $80.1M | ||
| Q4 24 | $308.6M | $143.5M | ||
| Q3 24 | $312.5M | $48.6M | ||
| Q2 24 | $302.6M | $14.6M | ||
| Q1 24 | $251.4M | $71.3M |
总债务ICUISVC
| Q4 25 | — | $5.5B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $5.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ICUISVC
| Q4 25 | $2.1B | $646.1M | ||
| Q3 25 | $2.1B | $647.9M | ||
| Q2 25 | $2.1B | $695.9M | ||
| Q1 25 | $2.0B | $734.6M | ||
| Q4 24 | $2.0B | $851.9M | ||
| Q3 24 | $2.0B | $929.0M | ||
| Q2 24 | $2.0B | $1.0B | ||
| Q1 24 | $2.1B | $1.1B |
总资产ICUISVC
| Q4 25 | $4.1B | $6.5B | ||
| Q3 25 | $4.1B | $7.0B | ||
| Q2 25 | $4.1B | $6.9B | ||
| Q1 25 | $4.2B | $7.0B | ||
| Q4 24 | $4.2B | $7.1B | ||
| Q3 24 | $4.3B | $7.1B | ||
| Q2 24 | $4.3B | $7.1B | ||
| Q1 24 | $4.3B | $7.2B |
负债/权益比ICUISVC
| Q4 25 | — | 8.52× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.85× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $-18.5M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $-95.2M |
| 自由现金流率自由现金流/营收 | 6.6% | -32.1% |
| 资本支出强度资本支出/营收 | 4.6% | 25.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | $-107.0M |
8季度趋势，按日历期对齐
经营现金流ICUISVC
| Q4 25 | $60.6M | $-18.5M | ||
| Q3 25 | $56.7M | $98.1M | ||
| Q2 25 | $11.2M | $-7.0K | ||
| Q1 25 | $51.3M | $38.2M | ||
| Q4 24 | $40.2M | $-9.7M | ||
| Q3 24 | $36.1M | $106.2M | ||
| Q2 24 | $82.0M | $43.8M | ||
| Q1 24 | $45.8M | $-926.0K |
自由现金流ICUISVC
| Q4 25 | $36.0M | $-95.2M | ||
| Q3 25 | $27.6M | $57.9M | ||
| Q2 25 | $-8.5M | $-46.6M | ||
| Q1 25 | $36.7M | $-23.2M | ||
| Q4 24 | $16.1M | $-88.9M | ||
| Q3 24 | $16.2M | $24.1M | ||
| Q2 24 | $62.5M | $-22.3M | ||
| Q1 24 | $29.9M | $-77.2M |
自由现金流率ICUISVC
| Q4 25 | 6.6% | -32.1% | ||
| Q3 25 | 5.1% | 15.3% | ||
| Q2 25 | -1.5% | -11.5% | ||
| Q1 25 | 6.1% | -6.9% | ||
| Q4 24 | 2.6% | -24.9% | ||
| Q3 24 | 2.7% | 6.2% | ||
| Q2 24 | 10.5% | -5.4% | ||
| Q1 24 | 5.3% | -23.0% |
资本支出强度ICUISVC
| Q4 25 | 4.6% | 25.9% | ||
| Q3 25 | 5.4% | 10.6% | ||
| Q2 25 | 3.6% | 11.5% | ||
| Q1 25 | 2.4% | 18.3% | ||
| Q4 24 | 3.8% | 22.2% | ||
| Q3 24 | 3.4% | 21.0% | ||
| Q2 24 | 3.3% | 16.0% | ||
| Q1 24 | 2.8% | 22.7% |
现金转化率ICUISVC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
SVC
暂无分部数据
